<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>PHA60104 Tutorial 5 by Yap Wei Hsum .</title>
      <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e</link>
      <description>Each group answer one question (based on assignment grouping) E.g. group 1 answer question 1</description>
      <language>en-us</language>
      <pubDate>2016-10-26 02:19:15 UTC</pubDate>
      <lastBuildDate>2018-12-13 16:26:33 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Question 1: </title>
         <author>sauharlee1303</author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295247937</link>
         <description><![CDATA[<div>Alicia Ng<br>Ch'ng Theck Ruey<br>Haziq Luqman<br><br>Many sectors play unique but increasingly interdependent roles in translating basic research into medicine. Discuss the roles of major pharmaceutical companies, small biotechnology startups, and government in drug discovery and development.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-21 23:19:19 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295247937</guid>
      </item>
      <item>
         <title>Question 2</title>
         <author>sauharlee1303</author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295247979</link>
         <description><![CDATA[<div>Lee Jia Jing<br>Lee Wai Leong<br>Cheong Pui Yi<br><br>Discuss the potential issues that facilitate and restrict partnerships/collaborations between academic and industry.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-21 23:19:34 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295247979</guid>
      </item>
      <item>
         <title>Question 3:</title>
         <author>sauharlee1303</author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295248005</link>
         <description><![CDATA[<div>Yeap Tze Huay<br>Bilal Tahir<br>Chan Le Roy<br><br>What is productivity gap in pharmaceutical industry? Suggest TWO (2) ways to overcome productivity gap.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-21 23:19:52 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295248005</guid>
      </item>
      <item>
         <title>Question 4:</title>
         <author>sauharlee1303</author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295248040</link>
         <description><![CDATA[<div>Chong Jia En<br>Chong Jia Yii<br>Dinie Aqilah<br><br>Describe the term ‘in-licensing’. Explain why in-licensing can be a beneficial strategy for growing a biotechnology startup.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-21 23:20:06 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295248040</guid>
      </item>
      <item>
         <title>Question 5:</title>
         <author>sauharlee1303</author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295248052</link>
         <description><![CDATA[<div>Josiah Mendel Sim<br>Lim Yee Hung<br>Mohanad<br><br>Between the Phase II clinical trial for ‘First in class’ and ‘Follower’ drugs, which one usually takes longer and cost significantly more?</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-21 23:20:16 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295248052</guid>
      </item>
      <item>
         <title>Question 6:</title>
         <author>sauharlee1303</author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295248097</link>
         <description><![CDATA[<div>P'ng Cheng<br>Ramkhalawon<br>Siaw Yau Wen<br><br>Briefly describe the following terms:<br>(a) Double blinded study<br>(b) Randomized control trial&nbsp;<br>(c) Primary Outcome Measure<br>(d) Placebo ‘run-in’ period</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-21 23:20:27 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/295248097</guid>
      </item>
      <item>
         <title>Question 6</title>
         <author></author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/296276735</link>
         <description><![CDATA[<div>(a) <strong>Double blinded study</strong><br>Both the test giver and the patients do not know which drug is real and which is a placebo.<br>(b) <strong>Randomized control trial<br></strong>Patients are randomly placed into either control or experimental groups regardless of background to reduce selection bias.<br>(c) <strong>Primary Outcome Measure<br></strong>The parameter measured in a study which is considered as the most important one among many parameters.<br>(d) <strong>Placebo 'run-in' period<br></strong>Time given for placebo used in patients to be removed from the body before a new drug is used.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-24 03:54:13 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/296276735</guid>
      </item>
      <item>
         <title>Question 3</title>
         <author></author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/296277139</link>
         <description><![CDATA[<div>1) Productivity gap is the difference between the increase in R&amp;D expenditures and the decline in the number of drugs approved by FDA/year<br><br>2) - Market expansion<br>     - Mergers and acquisition</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-24 03:56:38 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/296277139</guid>
      </item>
      <item>
         <title>Question 3 (Response to answer)</title>
         <author>sauharlee1303</author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/296446059</link>
         <description><![CDATA[<div>Can you explain a bit more on HOW the two ways that you have stated can be used to overcome the productivity gap.</div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-24 13:59:31 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/296446059</guid>
      </item>
      <item>
         <title>Question 4</title>
         <author></author>
         <link>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/297762302</link>
         <description><![CDATA[<div>In-licensing: A company takes on some of the financial or technological burdens associated with developing a product, then gets to share in its returns.<br><br>Benefits of in-licensing:</div><ul><li>Cost-effective, since the financial burden of product development is shared. </li><li>Lower risk for the company buying in: they can make deals based on promising pre-clinical or clinical results. </li><li>Holds significant appeal when compared to straight acquisitions or mergers. </li></ul><div><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2018-10-28 15:28:16 UTC</pubDate>
         <guid>https://padlet.com/weihsumyap1/6g9zjpi9v8e/wish/297762302</guid>
      </item>
   </channel>
</rss>
